Publications 2025

Abrantes R, Forcados C, Warren DJ, Santos-Ferreira L, Fleten KG, Senra E, Costa AF, Krpina K, Henrique R, Liberg AM, Rawat P, Gelebart P, McCormack E, Bjørge L, Davidson B, Greiff V, Costea DE, Pinto F, Flatmark K, Gomes C, Inderberg EM, Reis CA, Wälchli S (2025)
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors
6 (9), 102350
DOI 10.1016/j.xcrm.2025.102350, PubMed 40925376

Andersson Y, Løvstakken E, Herud TM, Waagene S, Flatmark K, Fleten KG (2025)
Intraperitoneal Perfusion with Cisplatin or Mitomycin C Improves Survival in Mice Bearing Peritoneal Metastases from Ovarian Cancer
32 (12), 9333-40 (in press)
DOI 10.1245/s10434-025-18025-x, PubMed 40788597

Andersson Y, Løvstakken E, Herud TM, Waagene S, Flatmark K, Fleten KG (2025)
ASO Visual Abstract: Intraperitoneal Perfusion with Cisplatin or Mitomycin C Improves Survival in Mice Bearing Peritoneal Metastases from Ovarian Cancer
32 (13), 10248-10249
DOI 10.1245/s10434-025-18467-3, PubMed 41046292

Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G et al. (2025)
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
85 (5), 956-972
DOI 10.1158/0008-5472.CAN-24-0323, PubMed 39700396

Publications 2023

Hyldbakk A, Fleten KG, Snipstad S, Åslund AKO, Davies CL, Flatmark K, Mørch Y (2023)
Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
48, 102656
DOI 10.1016/j.nano.2023.102656, PubMed 36646195

Ito I, Yousef AMG, Chowdhury S, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
83 (19), 3184-3191
DOI 10.1158/0008-5472.CAN-23-0013, PubMed 37433032

Publications 2022

Fleten KG, Hyldbakk A, Einen C, Benjakul S, Strand BL, Davies CL, Mørch Ý, Flatmark K (2022)
Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
20 (12)
DOI 10.3390/md20120744, PubMed 36547891

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
349, 1
DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388

Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
AXL inhibition improves BRAF-targeted treatment in melanoma
12 (1), 5076
DOI 10.1038/s41598-022-09078-z, PubMed 35332208

Publications 2021

Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Cancers, 13 (11), 2819
DOI 10.3390/cancers13112819

Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663

Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjornsson B, Rekdal O, Maelandsmo GM, Flatmark K (2021)
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Sci Rep, 11 (1), 6731
DOI 10.1038/s41598-021-86239-6

Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K (2021)
Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
J. Gastrointest. Oncol., 12 1, S191-+
DOI 10.21037/jgo-20-136

Publications 2020

Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
13 (8), 100793
DOI 10.1016/j.tranon.2020.100793, PubMed 32447231

Publications 2018

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
293, 183-192
DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259

Publications 2017

Andersson Y, Haavardtun SI, Davidson B, Dorum A, Fleten KG, Fodstad O, Flatmark K (2017)
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694

Publications 2016

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
34 (1), 51-62
DOI 10.1007/s10585-016-9829-3, PubMed 27812769

Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
2, 16081
DOI 10.1038/cddiscovery.2016.81, PubMed 28028438

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
7 (15), 19997-20015
DOI 10.18632/oncotarget.7671, PubMed 26918352

Publications 2015

Repetto-Llamazares AH, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, Pouget JP, Dahle J (2015)
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
10 (6), e0128816
DOI 10.1371/journal.pone.0128816, PubMed 26066655

Publications 2013

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569

Publications 2012

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
7, 165
DOI 10.1186/1748-717X-7-165, PubMed 23017053

Publications 2009

Storvold GL, Fleten KG, Olsen CG, Follestad T, Krokan HE, Schonberg SA (2009)
Docosahexaenoic Acid Activates Some SREBP-2 Targets Independent of Cholesterol and ER Stress in SW620 Colon Cancer Cells
Lipids, 44 (8), 673-683
DOI 10.1007/s11745-009-3324-4